Amber Specialty Chosen to Dispense Tavneos
The FDA has approved Tavneos, a first-in-class, oral therapy to treat a group of autoimmune diseases characterized by inflammation and damage to small blood vessels.
ChemoCentryx has chosen Amber Specialty Pharmacy to dispense Tavneos (avacopan) for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
The FDA approved Tavneos Oct. 8, 2021. It is the first of its kind orally administered selective complement 5a receptor inhibitor for this rare systemic disease in which over-activation of the complement pathway leads to inflammation and destruction of small blood vessels.
The approval was based on phase 3 data of 330 patients with ANCA-associated vasculitis in 20 countries. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks, as assessed by the Birmingham Vasculitis Activity Score.
The most common adverse reactions were: nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increase, and paresthesia.
Peter A. Merkel, M.D.
“Our work has helped lead to the first-in-a-decade approval of a medicine for ANCA-associated vasculitis. This is an important step forward in the treatment of this disease,” the trial’s co-primary academic investigator Peter A. Merkel, M.D., the chief of rheumatology at the Perelman School of Medicine at the University of Pennsylvania, said in a statement. “Patients will now have access to a new class of medication that provides beneficial effects for the treatment of ANCA-associated vasculitis.”
ANCA-associated vasculitis is a rare disease with an estimated prevalence of 200 to 400 cases per million people and is more prevalent in middle-age white men and women. The incidence has increased over time, likely due to improvements in diagnosis.
ChemoCentryx has developed TAVNEOS Connect, a patient support program. To learn more visit the website here.
Related: PANTHERx Rare Pharmacy Selected to Distribute Tavneos
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
